Prof. Maurice Michel (Mannheim, DE) discussed the innovation in minimally-invasive treatment of BPH in Monday’s Thematic Session 11. This type of treatment can be done in an out-patient setting and is less invasive than surgical treatment.
Traditionally, BPH has been treated with drugs or TURP. Alternatively, a period of watchful waiting can be offered to patients to observe their condition. The newly developed minimally-invasive treatment options can be helpful for patients in whom drugs were not effective and if TURP is not a suitable option. Michel stressed that the type of treatment should be selected by the urologist, not the general practitioner.
The main effect of minimally-invasive procedures is to decrease the patients’ IPSS. In this respect their effect is similar to most drugs for the treatment of BPH.
When asked which types of minimally-invasive treatment options will still be around in five years, Michel said that in his opinion botolinum toxin and ethanol will not stay in use. He does believe that the future lies in injectable agents, however it remains to be seen which agents will prove to be most efficient.